Inhibikase Therapeutics, Inc. insider trading
Every open-market purchase and sale by Inhibikase Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Insider purchases, 5 years $3M 1 trade by 1 insider
3 months later: median +18.1% (+13.2% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Inhibikase Therapeutics, Inc.’s insiders pay?
From November 19, 2021 to November 24, 2025, 5 insiders reported 5 open-market purchases and 0 sales not made under a pre-set plan in Inhibikase Therapeutics, Inc.
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Bellini Roberto | Director | 1 | — | — | 0 | — | October 23, 2024 |
| Kush Arvind | Director | 1 | — | — | 0 | — | October 23, 2024 |
| Munshi Amit | Director | 1 | — | — | 0 | — | October 23, 2024 |
| Sands Frank M. | 10% owner | 1 | — | — | 0 | — | November 24, 2025 |
| Werner Milton H. | President and CEO | 1 | — | — | 0 | — | November 19, 2021 |
← Back to Inhibikase Therapeutics, Inc. · Funds · Politicians